Vincerx Reports Positive Initial Clinical Data From VIP943 Phase 1 Dose-Escalation Study
8/10 05:49
(RTTNews) - Vincerx Pharma Inc. (VINC) announced two complete responses in the ongoing first-in-human, Phase 1 dose-escalation study of VIP943, the Company's next-generation antibody-drug conjugate or ADC being evaluated in relapsed/refractory acute myeloid leukemia or AML, highe...